Combination Treatments Access Improvement Framework

This document is a technical report that addresses the challenges related to patient access to combination treatments in healthcare. It outlines recent changes and discussions surrounding combination treatments, including a position statement published by the Competition & Markets Authority (CMA) in 2023, which acknowledges the necessity for collaboration among manufacturers to ensure cost-effectiveness. The report discusses the 2024 Voluntary Scheme on Pricing, Access, and Growth (VPAG), which supports solutions for cost-effectiveness issues. It highlights the consultation on the NHSE Commercial Framework and the progress made in increasing the availability of combination therapies. The report identifies cost-effectiveness barriers and presents opportunities for improvement. Additionally, it introduces a Conceptual Implementation Framework developed by Takeda, which aims to address these challenges by providing a comprehensive view of the regulatory and access systems. The report concludes by emphasizing the need for ongoing discussions among stakeholders to enhance patient access to these treatments.